Loading...
Please wait, while we are loading the content...
Similar Documents
miR-1, miR-21, and galectin-3 in hypertensive patients with symptomatic heart failure and left ventricular hypertrophy.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Tomaniak, Mariusz Sygitowicz, Grażyna Błaszczyk, Olga Kołtowski, Łukasz Puchta, Dominika Malesa, Karolina Kochanowski, Janusz Sitkiewicz, Dariusz Filipiak, Krzysztof Jerzy |
| Copyright Year | 2018 |
| Abstract | INTRODUCTION Left ventricular hypertrophy (LVH) is known as an independent risk factor for coronary heart disease, heart failure (HF), stroke, and sudden cardiac arrest. LVH implicates changes in the architecture of myocardial tissue, which consist of perivascular and myocardial fibrosis, as well as medial thickening of intramyocardial coronary arteries, in addition to cardiomyocyte hypertrophy [1–3]. The impact of miR-1 level on cardiac hypertrophy and cardiomyocyte apoptosis has been recently suggested [3, 4]. Also, the association between miR-21 and galectin-3 (gal-3) levels and maladaptive cardiac remodelling, fibrosis, and inflammation has been described [5, 6]. Nevertheless, the synergistic role of these molecules in LVH has not been explained to date. We analysed the expressions of miR-1, miR-21, and gal-3 concentration in patients with symptomatic HF (SHF) and a history of hypertension and LVH revealed in echocardiography. |
| Starting Page | 1009 |
| Ending Page | 1011 |
| Page Count | 3 |
| File Format | PDF HTM / HTML |
| DOI | 10.5603/KP.2018.0117 |
| PubMed reference number | 29905364 |
| Journal | Medline |
| Volume Number | 76 |
| Issue Number | 6 |
| Journal | Kardiologia polska |
| Alternate Webpage(s) | https://ojs.kardiologiapolska.pl/kp/article/download/KP.2018.0117/9766 |
| Alternate Webpage(s) | https://doi.org/10.5603/KP.2018.0117 |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
